Aurora Cannabis stock
ACBNASDAQAurora Cannabis Inc., HealthcareISIN CA05156X8504
44Score 44 out of 100, Weak
Price and trend
81 / 100
Price history
+10% in one yearThe chart shows daily closes over 12 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 40% above it.
Since September 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Overheated: the price has risen very quickly lately (RSI 79).
The price is 10% below its 52-week high. Largest decline in 12 years: 100% (January 2018 to July 2026).
Chart figures for advanced users
- SMA 50$4.23
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$3.57
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)79
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$2.58
- The lowest closing price of the last twelve months.
- Resistance$5.57
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Aurora Cannabis Inc. belongs to the Drug Manufacturers (Specialty & Generic) industry (Canada) and, with a market value of $328.07M, is number 77 of 78 companies in its industry on MEQIRI.
- In fiscal 2026 it reported revenue of $225.22M (down 6.6% year on year) and a loss of $85.54M.
- MEQIRI Score 44 out of 100 (Weak): rank 478 of 714 in Healthcare, median 53.
Show more
- Our model puts fair value at $2.34, with the price 116% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $58.74M, financial debt $15.06M.Stability 55
Weaknesses
- DilutionShare count up 486% since 2020.Capital allocation 18
- Above fair valuePrice 116% above the fair value of $2.34.Valuation 23
- Loss-makingLoss of $56.42M over the last 12 months.Fundamentals 17
Its standout strengths are technical analysis and momentum, while capital allocation and fundamentals hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 42 to 44.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
- high price swings
What lowers it
- price near its 52-week high
Valuation
Valuation signal
Significantly overvaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $1.56 and expensive above $4.68 (uncertainty very high, based on the price swings of the past year).
Calculated with a cost of equity of 8.2%. At 9.2% the fair value would be $2.20, at 7.2% it would be $2.54.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue fell 20% on the twelve months before. Revenue has grown strongly since 2016, at around 82% per year. From 2016 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2026: gross 43%, operating −15%, net not measured. From 2016 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Debt & balance sheet
latest quarterDebt is low, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 3 Feb 2027in 83 days
- Last reported
- 5 Nov 2026EPS reported −0.22 (expected −0.03)below expectations
Analyst estimates
Earnings estimates have barely changed since 4 Nov 2026.
- Earnings per share
- −0.17+1.0%
- Revenue
- $208.56M−1.1%
- Earnings per share
- 0.11−1.7%
- Revenue
- $227.63M−1.1%
MEQIRI has stored the estimates since 4 Nov 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases or sales in the last 6 months.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Aurora Cannabis
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 44
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (Specialty & Generic)
The next larger and next smaller companies by market value
- EvotecEVT.DE $624.43M32
- Alpha TeknovaTKNO $541M43
- EvolusEOLS $491.12M45
- KamadaKMDA $468.95M66
- Aquestive TherapeuticsAQST $449.96M29
- BoironBOI.PA $371.89M56
- PharmaSGP HoldingPSG.DE $371.49M80
- Emergent BioSolutionsEBS $310.55M24
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Mar 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = CA$1.4235)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 7 Nov 2025)
- Valuation signal Overvalued since 11 Nov 2026, previously Fairly valued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.